Mega Lifesciences stock: Finam gives Mega Lifesciences stock a Buy rating

Published on 10/24/2026 at 03:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached THB 3,547.18 million, up 3.72 percent year over year. Mega Lifesciences stock has a THB 44.60 target from Finam.

Profit growth and upcoming dates

Finam assigned a Buy rating and a THB 44.60 target on October 15, 2026.
Reported net profit grew 33.1 percent in the first half of 2026.
Mega Lifesciences is scheduled to announce third-quarter earnings on November 12, 2026.

Mega Lifesciences stock, healthcare, analyst rating, profit growth, SET, Illustration mit AI erstellt.

Mega Lifesciences drew a Buy rating from Finam on October 15, 2026, with a 12-month target of THB 44.60, according to Finmarket. The analyst case centers on branded-product expansion in Asia and Africa and operating efficiency in the company's logistics platform.

Profit growth supports the rating

Mega Lifesciences reported second-quarter revenue of THB 3,547.18 million, compared with THB 3,420.07 million in the same quarter of 2025. That represents growth of 3.72 percent. Net income excluding extra items reached THB 514.61 million, up from THB 390.92 million, while net margin increased from 11.40 percent to 14.50 percent, according to Simply Wall St on October 14, 2026.

What does the growth mean for margins?

The figures point to profitability as the central test for the analyst view. Revenue growth was positive, but the 3.10 percentage-point increase in net margin and the 31.65 percent rise in adjusted net income provide the stronger evidence for the THB 44.60 target.

First-half figures set the next test

The investor-relations page reported 12.5 percent year-over-year operating-revenue growth, 33.8 percent EBITDA growth and 33.1 percent reported net-profit growth for the first half of 2026. The same page lists the next earnings announcement for November 12, 2026 and the earnings conference call for November 13, 2026, according to Mega Lifesciences.

SET valuation remains in view

Mega Lifesciences closed at THB 34.50 on the SET on October 22, 2026. The quoted 52-week range was THB 28.50 to THB 40.00, placing the close 13.75 percent below the yearly high. Market capitalization stood at THB 30.1 billion on the same date. The combination of stronger margins and a scheduled November report gives investors a clear benchmark for the next update.